// App-Quantinova.ai

: Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Lumbar Intrathecal Bolus Administrations of Antisense Oligonucleotide (ISIS 814907; BIIB080) Targeting Tau mRNA in Patients with Mild Alzheimer’s Disease

Researchers

Presenter

  • Catherine J Mummery

Principal Investigators

  • Candice Junge

  • Holly B Kordasiewicz

  • Laurence Mignon

  • Katrina M Moore

  • Chris Yun

  • Tiffany L Baumann

  • Dan Li

  • Daniel A Norris

  • Rebecca Crean

  • Danielle Graham

  • Ellen Huang

  • Elena Ratti

  • Roger M Lane

Medical Centers

  • Ionis Pharmaceuticals Inc.

  • Biogen

  • University CollegeLondon, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Alzheimer's disease

Biomarkers

  • Cerebrospinal fluid

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Open Label

  • Controlled

  • First-In-Human

Phase

  • I

Study Id's

  • NCT03186989

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved